SCHEMBL223946

SCHEMBL223946

CC(=O)Oc1ccc(C=Cc2ccccc2N)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.58
▸ MAPT P10636 3/20 0.58
▸ LMNA P02545 3/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ TTR P02766 1/20 0.58
▸ TP53 P04637 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ CYP19A1 P11511 1/20 0.54
▸ TUBB4A P04350 3/20 0.50
▸ TUBB P07437 3/20 0.50
▸ TUBA3C P0DPH7 3/20 0.50
▸ TUBA1B P68363 3/20 0.50
▸ TUBA4A P68366 3/20 0.50
▸ TUBB4B P68371 3/20 0.50
▸ TUBB3 Q13509 3/20 0.50
▸ TUBB2A Q13885 3/20 0.50
▸ TUBB8 Q3ZCM7 3/20 0.50
▸ TUBA3E Q6PEY2 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL223945 1.00 KMT2A (0.58) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL10941170 0.89 KMT2A (0.67) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL224281 0.85 KMT2A (0.62) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL224282 0.85 KMT2A (0.62) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL716756 0.82 KMT2A (0.71) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL716755 0.82 KMT2A (0.71) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL10941162 0.82 MAPT (0.81) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL2451780 0.82 MAPT (0.81) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL11354408 0.82 MAPT (0.81) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL228516 0.81 KDM4E (0.57) KMT2AMAPTLMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1577288-B1 Selective estrogen receptor modulators EISAI R&D MAN CO LTD (JP) 2014-07-23 — — EP disclosed
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 — — US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 — — US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 — — US disclosed
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 — — US disclosed
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 — — US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 — — US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 KMT2A 371/4885MAPT 3989/4885LMNA 3237/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 KMT2A 216/4885MAPT 2593/4885LMNA 1494/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 KMT2A 455/4885MAPT 3856/4885LMNA 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback